GL Pharm Tech

At a glance

GL Pharm Tech filed 30 disclosures in the last 12 months, including 2 insider, 2 5% holder and 1 m&a. The most recent key filing was on Aug 6.

Revenue for 2025 was ₩35.3B, up 35.4% on 2024. Operating margin was 0.8% against -6.8% a year earlier. Debt was 145% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩19.1B and operating profit of ₩265.6M.

The 2025 annual report lists 32 employees with an average tenure of 2.6 years and average pay of ₩46.5M. Its 5 directors and auditors were paid ₩56.6M each on average. It paid no cash dividend for 2025. 더블유사이언스주식회사 and related parties held 29.77% at year end.

From the 2025 annual report

Staff: 32 (17 men, 15 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩1.5B. Directors and auditors: 5, paid ₩226.5M in total.

No cash dividend was paid for 2025.

Largest shareholder

더블유사이언스주식회사 holds 29.77%; with 0 related parties the group holds 29.77% of common shares at year end (from 30.00% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary